Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting

the CuVIC trial (effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial

Susumu Takase, Tetsuya Matoba, Soichi Nakashiro, Yasushi Mukai, Shuujirou Inoue, Keiji Oi, Taiki Higo, Shunsuke Katsuki, Masao Takemoto, Nobuhiro Suematsu, Kenichi Eshima, Kenji Miyata, Mitsutaka Yamamoto, Makoto Usui, Kenji Sadamatsu, Shinji Satoh, Toshiaki Kadokami, Kiyoshi Hironaga, Ikuyo Ichi, Koji Todaka & 3 others Junji Kishimoto, Kensuke Egashira, Kenji Sunagawa

研究成果: ジャーナルへの寄稿記事

10 引用 (Scopus)

抄録

Objectives - We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. Approach and Results - We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy, S versus ezetimibe [10 mg/d]+statin combinational therapy, E+S). We defined target vessel dysfunction as the primary composite outcome, which comprised target vessel failure during treatment and at the 6- to 8-month follow-up coronary angiography and coronary endothelial dysfunction determined via intracoronary acetylcholine testing performed in cases without target vessel failure at the follow-up coronary angiography. Coadministration of ezetimibe with statins further lowered low-density lipoprotein cholesterol levels (83±23 mg/dL in S versus 67±23 mg/dL in E+S; P<0.0001), with significant decreases in oxidized low-density lipoprotein and oxysterol levels. Among patients without target vessel failure, 46 out of 89 patients (52%) in the S arm and 34 out of 96 patients (35%) in the E+S arm were found to have coronary endothelial dysfunction (P=0.0256), and the incidence of target vessel dysfunction at follow-up was significantly decreased in the E+S arm (69/112 (62%) in S versus 47/109 (43%) in E+S; P=0.0059). A post hoc analysis of post-treatment low-density lipoprotein cholesterol-matched subgroups revealed that the incidence of both target vessel dysfunction and coronary endothelial dysfunction significantly decreased in the E+S arm, with significant reductions in oxysterol levels. Conclusions - The CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting) has shown that ezetimibe with statins, compared with statin monotherapy, improves functional prognoses, ameliorating endothelial dysfunction in stented coronary arteries, and was associated with larger decreases in oxysterol levels.

元の言語英語
ページ(範囲)350-358
ページ数9
ジャーナルArteriosclerosis, thrombosis, and vascular biology
37
発行部数2
DOI
出版物ステータス出版済み - 2 2017

Fingerprint

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Vessels
Randomized Controlled Trials
Coronary Angiography
LDL Cholesterol
Coronary Artery Disease
Incidence
Treatment Failure
Acetylcholine
Ezetimibe
Therapeutics
Oxysterols

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting : the CuVIC trial (effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial. / Takase, Susumu; Matoba, Tetsuya; Nakashiro, Soichi; Mukai, Yasushi; Inoue, Shuujirou; Oi, Keiji; Higo, Taiki; Katsuki, Shunsuke; Takemoto, Masao; Suematsu, Nobuhiro; Eshima, Kenichi; Miyata, Kenji; Yamamoto, Mitsutaka; Usui, Makoto; Sadamatsu, Kenji; Satoh, Shinji; Kadokami, Toshiaki; Hironaga, Kiyoshi; Ichi, Ikuyo; Todaka, Koji; Kishimoto, Junji; Egashira, Kensuke; Sunagawa, Kenji.

:: Arteriosclerosis, thrombosis, and vascular biology, 巻 37, 番号 2, 02.2017, p. 350-358.

研究成果: ジャーナルへの寄稿記事

Takase, Susumu ; Matoba, Tetsuya ; Nakashiro, Soichi ; Mukai, Yasushi ; Inoue, Shuujirou ; Oi, Keiji ; Higo, Taiki ; Katsuki, Shunsuke ; Takemoto, Masao ; Suematsu, Nobuhiro ; Eshima, Kenichi ; Miyata, Kenji ; Yamamoto, Mitsutaka ; Usui, Makoto ; Sadamatsu, Kenji ; Satoh, Shinji ; Kadokami, Toshiaki ; Hironaga, Kiyoshi ; Ichi, Ikuyo ; Todaka, Koji ; Kishimoto, Junji ; Egashira, Kensuke ; Sunagawa, Kenji. / Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting : the CuVIC trial (effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial. :: Arteriosclerosis, thrombosis, and vascular biology. 2017 ; 巻 37, 番号 2. pp. 350-358.
@article{727fb5990d2241a4976beae7e9066142,
title = "Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting: the CuVIC trial (effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial",
abstract = "Objectives - We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. Approach and Results - We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy, S versus ezetimibe [10 mg/d]+statin combinational therapy, E+S). We defined target vessel dysfunction as the primary composite outcome, which comprised target vessel failure during treatment and at the 6- to 8-month follow-up coronary angiography and coronary endothelial dysfunction determined via intracoronary acetylcholine testing performed in cases without target vessel failure at the follow-up coronary angiography. Coadministration of ezetimibe with statins further lowered low-density lipoprotein cholesterol levels (83±23 mg/dL in S versus 67±23 mg/dL in E+S; P<0.0001), with significant decreases in oxidized low-density lipoprotein and oxysterol levels. Among patients without target vessel failure, 46 out of 89 patients (52{\%}) in the S arm and 34 out of 96 patients (35{\%}) in the E+S arm were found to have coronary endothelial dysfunction (P=0.0256), and the incidence of target vessel dysfunction at follow-up was significantly decreased in the E+S arm (69/112 (62{\%}) in S versus 47/109 (43{\%}) in E+S; P=0.0059). A post hoc analysis of post-treatment low-density lipoprotein cholesterol-matched subgroups revealed that the incidence of both target vessel dysfunction and coronary endothelial dysfunction significantly decreased in the E+S arm, with significant reductions in oxysterol levels. Conclusions - The CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting) has shown that ezetimibe with statins, compared with statin monotherapy, improves functional prognoses, ameliorating endothelial dysfunction in stented coronary arteries, and was associated with larger decreases in oxysterol levels.",
author = "Susumu Takase and Tetsuya Matoba and Soichi Nakashiro and Yasushi Mukai and Shuujirou Inoue and Keiji Oi and Taiki Higo and Shunsuke Katsuki and Masao Takemoto and Nobuhiro Suematsu and Kenichi Eshima and Kenji Miyata and Mitsutaka Yamamoto and Makoto Usui and Kenji Sadamatsu and Shinji Satoh and Toshiaki Kadokami and Kiyoshi Hironaga and Ikuyo Ichi and Koji Todaka and Junji Kishimoto and Kensuke Egashira and Kenji Sunagawa",
year = "2017",
month = "2",
doi = "10.1161/ATVBAHA.116.308388",
language = "English",
volume = "37",
pages = "350--358",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting

T2 - the CuVIC trial (effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial

AU - Takase, Susumu

AU - Matoba, Tetsuya

AU - Nakashiro, Soichi

AU - Mukai, Yasushi

AU - Inoue, Shuujirou

AU - Oi, Keiji

AU - Higo, Taiki

AU - Katsuki, Shunsuke

AU - Takemoto, Masao

AU - Suematsu, Nobuhiro

AU - Eshima, Kenichi

AU - Miyata, Kenji

AU - Yamamoto, Mitsutaka

AU - Usui, Makoto

AU - Sadamatsu, Kenji

AU - Satoh, Shinji

AU - Kadokami, Toshiaki

AU - Hironaga, Kiyoshi

AU - Ichi, Ikuyo

AU - Todaka, Koji

AU - Kishimoto, Junji

AU - Egashira, Kensuke

AU - Sunagawa, Kenji

PY - 2017/2

Y1 - 2017/2

N2 - Objectives - We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. Approach and Results - We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy, S versus ezetimibe [10 mg/d]+statin combinational therapy, E+S). We defined target vessel dysfunction as the primary composite outcome, which comprised target vessel failure during treatment and at the 6- to 8-month follow-up coronary angiography and coronary endothelial dysfunction determined via intracoronary acetylcholine testing performed in cases without target vessel failure at the follow-up coronary angiography. Coadministration of ezetimibe with statins further lowered low-density lipoprotein cholesterol levels (83±23 mg/dL in S versus 67±23 mg/dL in E+S; P<0.0001), with significant decreases in oxidized low-density lipoprotein and oxysterol levels. Among patients without target vessel failure, 46 out of 89 patients (52%) in the S arm and 34 out of 96 patients (35%) in the E+S arm were found to have coronary endothelial dysfunction (P=0.0256), and the incidence of target vessel dysfunction at follow-up was significantly decreased in the E+S arm (69/112 (62%) in S versus 47/109 (43%) in E+S; P=0.0059). A post hoc analysis of post-treatment low-density lipoprotein cholesterol-matched subgroups revealed that the incidence of both target vessel dysfunction and coronary endothelial dysfunction significantly decreased in the E+S arm, with significant reductions in oxysterol levels. Conclusions - The CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting) has shown that ezetimibe with statins, compared with statin monotherapy, improves functional prognoses, ameliorating endothelial dysfunction in stented coronary arteries, and was associated with larger decreases in oxysterol levels.

AB - Objectives - We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. Approach and Results - We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy, S versus ezetimibe [10 mg/d]+statin combinational therapy, E+S). We defined target vessel dysfunction as the primary composite outcome, which comprised target vessel failure during treatment and at the 6- to 8-month follow-up coronary angiography and coronary endothelial dysfunction determined via intracoronary acetylcholine testing performed in cases without target vessel failure at the follow-up coronary angiography. Coadministration of ezetimibe with statins further lowered low-density lipoprotein cholesterol levels (83±23 mg/dL in S versus 67±23 mg/dL in E+S; P<0.0001), with significant decreases in oxidized low-density lipoprotein and oxysterol levels. Among patients without target vessel failure, 46 out of 89 patients (52%) in the S arm and 34 out of 96 patients (35%) in the E+S arm were found to have coronary endothelial dysfunction (P=0.0256), and the incidence of target vessel dysfunction at follow-up was significantly decreased in the E+S arm (69/112 (62%) in S versus 47/109 (43%) in E+S; P=0.0059). A post hoc analysis of post-treatment low-density lipoprotein cholesterol-matched subgroups revealed that the incidence of both target vessel dysfunction and coronary endothelial dysfunction significantly decreased in the E+S arm, with significant reductions in oxysterol levels. Conclusions - The CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting) has shown that ezetimibe with statins, compared with statin monotherapy, improves functional prognoses, ameliorating endothelial dysfunction in stented coronary arteries, and was associated with larger decreases in oxysterol levels.

UR - http://www.scopus.com/inward/record.url?scp=85003953013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003953013&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.116.308388

DO - 10.1161/ATVBAHA.116.308388

M3 - Article

VL - 37

SP - 350

EP - 358

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 2

ER -